About tarlatamab
Bispecific T-cell engager antibody
Used for
- Treats extensive-stage small-cell lung cancer that has progressed during or after platinum-based chemotherapy.
Usual adult dose
Intravenous infusion: 1 mg on day 1, then 10 mg on days 8 and 15; afterward, 10 mg every two weeks.
Common side effects
- Cytokine release syndrome
- Fatigue
- Fever
- Decreased appetite
Important warnings
- Can cause life-threatening cytokine release syndrome; monitoring and emergency treatment may be needed.
- Can cause serious neurologic problems, including confusion, seizures, or trouble speaking.
- Infusion requires a step-up schedule and monitoring after initial doses.
- Infections and low blood-cell counts can occur.
Pregnancy
May harm an unborn baby; pregnancy status should be checked before treatment.
Breastfeeding
Breastfeeding is not recommended during treatment and for two months after the final dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.